LEADERSHIP

Guiding our quest to become one of the world’s leading biotechnology companies

Executive Committee, MorphoSys AG

Jean-Paul Kress, MD Chief Executive Officer

Jean-Paul Kress, MD

Chief Executive Officer

Dr. Jean-Paul Kress joined MorphoSys in September 2019. He has a strong track record of commercial and (operational) strategic leadership in various senior management roles in North America and Europe. His focus has been on operations, corporate development, and especially the commercialization of innovative products addressing unmet medical needs across diverse disease indications.

Prior to joining MorphoSys, Dr. Kress served as President and Chief Executive Officer at Syntimmune, a clinical-stage biotechnology company developing differentiated drug candidates in a wide range of autoimmune diseases, which was acquired by Alexion in November 2018.

Among other assignments, he was Executive Vice President, President of International and Head of Global Therapeutic Operations at Biogen, and Senior Vice President, Head of North America at Sanofi Genzyme, where he was instrumental in launching dupilumab, the first biologic agent approved in atopic dermatitis.

Previously, he was President and Chief Executive Officer of Sanofi Pasteur MSD, and gained further experience in positions at Gilead, AbbVie, and Eli Lilly.

Dr. Kress received an MD degree from Faculté Necker-Enfants Malades in Paris, and graduate and post-graduate degrees in biochemistry and in molecular and cellular pharmacology from École Normale Supérieure in Paris.

MEMBERSHIPS IN STATUTORY SUPERVISORY BOARDS AND/OR IN COMPARABLE DOMESTIC OR FOREIGN SUPERVISORY BODIES OF COMMERCIAL ENTERPRISES

Erytech Pharma SA, Lyon, France (publicly listed company) Member of the Board of Directors

As of March 2020

Charlotte Lohmann SVP, General Counsel

Charlotte Lohmann

SVP, General Counsel

Charlotte Lohmann joined MorphoSys in May 2012. She is a very experienced lawyer with more than 20 years of professional practice, having worked in both top tier international audit and law firms as well as in publicly listed biotech companies.

She is an accomplished executive who has established solution-oriented legal departments with a focus on performance, effectiveness and making the legal department a true business partner.

She has been successful in setting up and executing international projects as well as public listings on Frankfurt Stock Exchange and Nasdaq and has vast experience in advising management and supervisory boards (both as General Counsel and supervisory board member).

Prior to joining MorphoSys she worked for Wilex AG as Sr. VP Legal Affairs & Human Resources and for KPMG as a corporate lawyer.

Charlotte Lohmann holds a Law Degree from the University of Munich and is an accredited lawyer in Germany.

Malte Peters, MD Chief Research and Development Officer

Malte Peters, MD

Chief Research
and Development Officer

Dr. Malte Peters joined MorphoSys from Sandoz International, Holzkirchen, Germany, where he was Global Head of Clinical Development of the Biopharmaceuticals Business Unit.

Prior to this position, he served as Clinical Head and Site Head for Basel and East Hanover in the department of Oncology Translational Medicine at Novartis. Dr. Peters held teaching appointments in Internal Medicine and Biochemistry at the University of Mainz, Germany.

Dr. Peters received his MD degree from the Freie Universität Berlin, Germany, and was trained at the Universities of Padova, Italy and Bochum and Berlin, Germany.

After scientific work at different universities he received his habilitation in Internal Medicine at the University of Mainz, Germany. Subsequently, he served as Research Scientist at the Amgen Research Institute in Toronto, Canada, as Director of Cancer Research at Merck KGaA in Darmstadt, Germany and as Medical Director at Micromet AG in Munich, Germany.

MEMBERSHIPS IN STATUTORY SUPERVISORY BOARDS AND/OR IN COMPARABLE DOMESTIC OR FOREIGN SUPERVISORY BODIES OF COMMERCIAL ENTERPRISES

Tango Therapeutics, Cambridge, MA, US (not publicly listed company; group mandate) Member of the Board of Directors

As of March 2020

Barbara Krebs-Pohl, PhD SVP, Head of Global BD&L and Alliance Management

Barbara Krebs-Pohl, PhD

SVP, Head of Global BD&L
and Alliance Management

Dr. Barbara Krebs-Pohl is a highly regarded business development executive with an outstanding track record of accomplishment of revenues and forging successful alliances with pharma and biotechnology companies worldwide.

Since joining MorphoSys in 1998, Dr. Krebs-Pohl has successfully led R&D teams, international alliances and negotiation teams spanning a broad variety of deal structures. She has been instrumental in program search & evaluation, portfolio strategy and a multitude of transactions, including the in-licensing of tafasitamab from Xencor, the long-term HuCAL alliance with Novartis and the co-development and co-commercialization partnership with Incyte. She is also the winner of the "Astra Zeneca Business Development Executive of the Year 2013" Award.

Prior to joining MorphoSys, Dr. Krebs-Pohl earned the opportunity to work with Nobel Prize winner Sir Greg Winter at MRC/LMB Cambridge, UK. She holds a PhD from the University of Mainz in Immunology, theoretical Physics and Biochemistry. She is a Master of Science (MSc) Chemistry from the University of Cologne and further trained at the RWTH Aachen University with focus on Medical Biology and Bacteriology.

Jens Holstein Chief Financial Officer

Jens Holstein

Chief Financial Officer

Jens Holstein joined MorphoSys from Fresenius Kabi AG, where he most recently served as Regional CFO for the region EME (Europe/Middle East) and as Managing Director of Fresenius Kabi Deutschland GmbH.

Over nearly 16 years at Fresenius he had held a variety of financial and general management positions. From 2006 to 2010, he was Regional Chief Financial Officer of Fresenius Kabi Asia Pacific Ltd., based in Hong Kong. Prior to this appointment, Mr. Holstein was Managing Director of Fresenius ProServe GmbH and Chief Financial Officer and Labor Director of the company’s subsidiary Wittgensteiner Kliniken AG. Earlier positions within Fresenius included General Manager of Hospital Care GmbH, Commercial Manager of the Projects & Service business unit of Fresenius AG, and Commercial Manager of Hospitalia International GmbH.

Prior to joining Fresenius, Mr. Holstein spent several years in the consulting industry, with positions in Frankfurt and London.

Mr. Holstein holds a diploma in business administration from the University of Münster.

MEMBERSHIPS IN STATUTORY SUPERVISORY BOARDS AND/OR IN COMPARABLE DOMESTIC OR FOREIGN SUPERVISORY BODIES OF COMMERCIAL ENTERPRISES

No other memberships.


As of July 2020

Roland Wandeler, PhD Chief Operating Officer

Roland Wandeler, PhD

Chief Operating Officer

Dr. Roland Wandeler joined MorphoSys in May 2020. He has more than 15 years of commercial leadership and general management experience in the pharmaceutical and biotechnology industry, with a strong track record of building and leading sizable affiliates and US franchises across multiple therapeutic areas, including oncology and hematology. Prior to MorphoSys, Dr. Wandeler held positions of increasing responsibility at Amgen, Inc., including General Manager Germany in Munich and General Manager Spain & Portugal in Barcelona, before most recently serving as Corporate Vice President and General Manager of Amgen’s US Bone Health and Cardiology Business Unit in Thousand Oaks, California. Dr. Wandeler initially joined Amgen in 2006 in strategic planning for its international business. Subsequent highlights include sales and business unit leadership roles in Germany at the time of several launches across therapeutic areas. Dr. Wandeler began his career at Boston Consulting Group (BCG) in Zurich, Switzerland and Los Angeles, California, where he was a core member of BCG’s global Healthcare Practice as well as a Member of the Zurich and Los Angeles Management Teams.

Dr. Wandeler holds a M.Sc. in Chemical Engineering and a Doctorate in Technical Sciences from ETH Zurich.

MEMBERSHIPS IN STATUTORY SUPERVISORY BOARDS AND/OR IN COMPARABLE DOMESTIC OR FOREIGN SUPERVISORY BODIES OF COMMERCIAL ENTERPRISES

No other memberships.


As of May 2020

Maria Castresana SVP, Global Head of Human Resources

Maria Castresana

SVP, Global Head of Human Resources

Maria Castresana is a global HR Executive with extensive international experience in the pharmaceutical and chemical industry who has gained more than 20 years of professional experience in Spain, Germany and the USA.

Prior to joining MorphoSys in 2020, Maria Castresana held positions of increasing responsibility at Boehringer Ingelheim, a global pharmaceutical player that expanded in recent years into oncology and specialty. She lately served as Global Head of Talent, Leadership & Organizational Effectiveness. Among other assignments, she was Global Business Partner for Consumer Health Care and led the carve-out and sale of the business in the frame of BI's and Sanofi's SWAP of CHC and Animal Health business, which closed on January 1st, 2017. Furthermore, she spent several years in the USA and was instrumental in the set-up of new commercial launch teams for Oncology, Diabetes and Cardiovascular.

Previously, she also worked for Ecolab as European Compensation Manager and gained early experience at Bayer.

Maria Castresana received a Law Degree and a Business Administration Degree from the University of Deusto in Spain and a Masters in Human Resources from Rutgers University in the USA.

Daniel Palmacci SVP, Global Head of Technical Operations

Daniel Palmacci

SVP, Global Head of Technical Operations

Daniel Palmacci brings over 20 years of experience in the international pharmaceutical industry with responsibility for Manufacturing, Supply Chain and Operational Excellence, leading cross-functional teams responsible for Pharmaceutical cGMP Production of Biologics API and sterile Fill & Finish, Manufacturing Science & Technology and Launch Management of new biotech products and biosimilars.

Before joining MorphoSys he has been working in various senior roles at MSD and Novartis in Germany, Austria and Switzerland. He spent many years in the United States, where he was responsible for the construction of the new cGMP certified biopharmaceutical facility at Schering AG, Seattle. Later Daniel took over the responsibility for a biopharmaceutical manufacturing facility for Bayer HealthCare in the United States. He has a wide multicultural experience through international assignments in Germany, Italy, India, Brazil and the US.

Daniel holds a master’s degree in Chemistry and Process Engineering from the University of Berlin.

MorphoSys US Inc. Leadership Team

David Trexler President

David Trexler

President

David Trexler brings to MorphoSys US more than 30 years of experience in building commercial capabilities for international pharmaceutical companies. He has successfully executed numerous oncology product launches and possesses deep knowledge and understanding of marketing, sales, the access environment, and business development.

Before joining MorphoSys US, David served as SVP, Oncology Commercial for EMD Serono, the biopharmaceutical business of Merck KGaA, where he was responsible for building the company’s first commercial oncology footprint in the US. He also contributed to a successful launch of the first PD-L1 for metastatic Merkel cell carcinoma. At Eisai, David helped to build the Oncology Business Unit. With two company acquisitions and a variety of oncology product launches, he has gained invaluable experience in establishing commercial capabilities to support launches across breast cancer, myelodysplastic syndrome, cutaneous T-cell lymphoma, renal cell carcinoma, thyroid, and the chemotherapy-induced nausea and vomiting supportive care marketplace.

David earned an executive MBA from Fairleigh Dickinson University. He completed graduate work in public health at the University of South Florida. He also holds an undergraduate degree in biology, with honors, from Lenoir-Rhyne University.

Nuwan Kurukulasuriya, PhD SVP & Head, Global Medical Affairs

Nuwan Kurukulasuriya, PhD

SVP & Head, Global Medical Affairs

Nuwan Kurukulasuriya brings 20 years of academic, medical affairs and clinical development experience to MorphoSys. He started his industry career at Johnson & Johnson, where he developed an impressive repertoire of skills building customer-facing teams, expert in communicating with impact and translating scientific strategy into execution. Later, Nuwan joined Biogen’s Global Medical Affairs Leadership Team as Head of Research and Real World Evidence, where he championed an integrated, portfolio approach to data generation and dissemination. While at Biogen, Nuwan also successfully launched Tecfidera®, now generating $4B in annual revenues. More recently, as VP, Head of US Medical Affairs at Shire, Nuwan led large interdisciplinary teams across multiple therapeutic areas, including Hematology, Oncology, Immunology, Neurology, Ophthalmology and Rare Disease. At MorphoSys, Nuwan leads an innovative patient-centric medical organization, with an aptitude for informing real-world clinical practice and accelerating the development of life-saving therapies in the immuno-oncology space.

Nuwan has a PhD in Neuroscience from Wake Forest University School of Medicine and both an MS and BA (Honors) from the University of North Carolina at Greensboro. He has also received executive training in Health Economics and Outcomes Research at the Harvard School of Public Health.

Chris Mancill SVP, Head of Access & Policy

CHRIS mancill

SVP, Head of Access & Policy

Chris Mancill leads teams across government affairs, market access, and advocacy. His focus is ensuring that payers and policymakers understand the value that MorphoSys’ products represent.

Chris has 25 years of experience in access and policy at the global, federal, and state levels across US and international companies, including Amgen and Merck KGaA. He has a proven record of strategic leadership in public policy, pricing, and access for oncology and biotechnology products. Chris has been involved in a variety of biopharmaceutical launches. Earlier in his career, he held positions of increasing responsibility at the American Red Cross, the Healthcare Financial Management Association, and Avalere Health.

Chris has a master of arts from the University of Virginia and a bachelor of arts from Christopher Newport University.

Marcie Cain SVP, Head of US Human Resources

MARCIE CAIN

SVP, Head of US Human Resources

Marcie Cain leads the US Human Resources strategy and execution for MorphoSys US, in partnership with the leadership team. She oversees all aspects of human resources, including talent acquisition, total rewards, culture and engagement, HR business partnership, and organization and leadership development. Marcie is a collaborative and results-driven HR leader who is focused on ensuring that overall business strategies are translated into impactful and effective human resources programs. She is passionate about the important and meaningful work we do every day to serve our patients and our employees.

Marcie has built her career in HR leadership positions for several life science companies. Before joining MorphoSys US, she was the Head of Human Resources for Boston Heart Diagnostics, an advanced cardiovascular diagnostic testing business. Prior to that, she was the Global Head of Human Resources for HeartWare, a global medical device company, where she led the development and implementation of all HR initiatives to help drive the successful execution of business strategies and enable intense growth. Marcie worked for 10 years at Genzyme, one of the world’s leading biotechnology companies, where she held positions of increasing responsibility, including Vice President of Human Resources for both the Biosurgery and Genetic Testing businesses.

Marcie holds a BS in business and economics from Washington State University.

Chris Krawtschuk SVP, Head of Finance

CHRIS KRAWTSCHUK

SVP, Head of Finance

Chris Krawtschuk is a senior financial executive with over 20 years of experience in providing operational financial advice to enable appropriate capital allocation for commercial execution. He brings expertise across a broad spectrum of complex accounting issues.

At MorphoSys US, Chris has been integral in recruiting and leading a finance and business operations team that includes controllership, financial analysis and planning, government pricing/gross to net, IT, procurement, treasury operations, and US facilities.

As VP, Lead Divisional Controller for Pfizer Inc., Chris provided financial leadership that supported business strategy, operational performance, and certain business development efforts. His responsibilities included providing advisory and financial reporting support to all of the Pfizer global businesses and support functions, providing technical training, and implementing new accounting pronouncements.

At PwC, Chris partnered with strategy and business development groups and advised some of the largest clients on complex transactions. He leveraged his experience to develop creative and innovative solutions to address client needs while balancing business, legal, accounting, tax and regulatory challenges. Chris specialized in providing accounting and financial reporting advice relating to acquisitions, divestitures, initial public offerings, capital markets transactions, and complex accounting and reporting issues related to structuring strategic alliances and joint ventures.

Chris received his BS in accounting from William Paterson University. He is a Certified Public Accountant.

Amy Wilson Head, US Compliance

Amy wilson

Head, US Compliance

Amy Wilson brings her ability as a strategic collaborator to MorphoSys US. She works to bolster business decision-making and performance management through the development and implementation of a foundational compliance management program.

Amy has more than 25 years of experience in the life sciences industry. She contributes proven technical compliance expertise that is informed by extensive brand sales, marketing, and operations experience.

Prior to joining MorphoSys US, Amy served as Enterprise Compliance Lead at Alexion. She also held the position of Compliance Monitoring and Risk Lead at Takeda. Leading up to her more recent compliance experiences, Amy worked in escalating sales, marketing, and patient support services roles at Eisai and Novartis.

In support of her evolving career, Amy most recently earned a master’s in jurisprudence from Seton Hall University School of Law. She also holds a bachelor of science from Drexel University and an MBA from Fairleigh Dickinson University.

Jeannette Bressi Head, US Communications

Jeanette Bressi

Head, US Communications

Jeanette Bressi leads US Communications strategy and execution. She is responsible for shaping and telling the MorphoSys US story, including employee communications, product launch support, and positioning MorphoSys US with key external stakeholders as it becomes a fully integrated biotechnology company. She is a passionate advocate for the healthcare industry and committed to improving the lives of patients.

With more than 20 years of global communications and community affairs experience, Jeanette joined MorphoSys from Parexel International. In her role there, she worked on global re-branding, digital transformation and helping to craft and tell the Parexel story.

Jeanette’s previous roles include building and managing Integra LifeSciences’ Communications Center of Excellence. She also has a decade of experience in the global pharmaceutical industry, including leading CV/Metabolics communications for Bristol-Myers Squibb, global healthcare technology communications for Johnson & Johnson, and 6 years of global consulting experience with Merck & Co. She holds a bachelor of arts in government from Georgetown University.

Stéphane Berthier, PharmD VP, Head of Sales & Marketing

STéPHANE BERTHIER, PharmD

VP, Head of Sales & Marketing

Stéphane Berthier has an impressive track record of hands-on experience in global and US sales and marketing, as well as global development and global project management in both oncology and hematology. He has demonstrated an ability to lead cross-functional teams, launch new drugs, and adapt to new environments and challenges.

Before he joined MorphoSys, Stéphane was the Global Commercial Head of Lymphoma and Leukemia for the Janssen division of Johnson & Johnson. He spent much of his career at Novartis Oncology in Europe and the US. Stéphane holds a doctorate of pharmacy from Paris Descartes University, as well as an MBA from Lancaster University in the UK.

Krishna Kadiyala VP, Head of Business Operation & Innovation

KRISHNA KADIYALA

VP, Head of Business Operation & Innovation

Krishna Kadiyala joined MorphoSys US with more than15 years of experience in the biopharma industry. He brings extensive experience in formulating and translating strategy into actionable goals to drive performance and growth. Krishna’s in-depth knowledge of the hematology/oncology space has informed his roles on multiple launches across a variety of indications and markets.

Krishna has a proven track record of commercial excellence, developing and executing transformational innovations for maximizing the short- and long-term value of the portfolio. His prior experience includes leadership roles at Spectrum, Novartis, and Merck.

Krishna received his MBA from The Wharton School, University of Pennsylvania. He also holds master’s degrees in both industrial engineering and statistics, and an undergraduate degree in production engineering.

Benjamin Looker VP, Head of US Legal

BENJAMIN LOOKER

VP, Head of US Legal

Benjamin Looker brings more than a decade of legal and compliance experience in the pharmaceutical industry to MorphoSys US. Ben is responsible for all legal matters for the company. He serves on the Senior Leadership Team, and counsels the Board of Directors on business initiatives, corporate structure, enforcement environment, and risk mitigation strategies.

Previously, Ben held roles of increasing responsibility at EMD Serono, the biopharmaceutical division of Merck KGaA, that culminated in his position as Associate General Counsel for Oncology. Ben also served as a corporate associate in the life sciences practice at Goodwin Procter LLP, an international law firm.

Ben received a BS summa cum laude from Boston College, and his law degree magna cum laude from Boston College Law School.

Learn About Our Partnerships